Dergiler / Turkish Journal of Gastroenterology / 2021 / Cilt: 32 - Sayı: 1

Intrahepatic Expression of C-C Motif ligand 5 in Patients with Chronic Hepatitis B

Sayfa
76–81
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusions: CHB patients have a significant accumulation of CCL5+ cells in the liver, and CCL5 may play a pathological role in hepatic inflammation of CHB.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background: C-C motif ligand 5 (CCL5) is reported to play a key role in acute and chronic liver diseases.
📊
Temel Bulgular & Veri:However, the association between CCL5 and chronic hepatitis B (CHB) remains to be explored.
💡
Sonuç & Katkı:Conclusions: CHB patients have a significant accumulation of CCL5+ cells in the liver, and CCL5 may play a pathological role in hepatic inflammation of CHB.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Background: C-C motif ligand 5 (CCL5) is reported to play a key role in acute and chronic liver diseases. However, the association between CCL5 and chronic hepatitis B (CHB) remains to be explored. We aimed to investigate the CCL5 expression in the liver tissues of CHB patients and compared the CCL5 expression among CHB patients with different stages of liver inflammation and fibrosis. Methods: Liver tissue specimens from 51 CHB patients who underwent liver biopsy and twelve healthy liver donors were included in the present study. CCL5 expression in the liver tissues was analyzed using immunohistochemistry. The hepatic inflammation grades and fibrotic stages of CHB patients were assessed by the Scheuer classification system. Results: Livers of CHB patients exhibited significantly accumulated CCL5+ cells when compared to those of healthy controls (42.80 ± 4.37 vs. 7.25 ± 0.99/HPF, P < .001). CHB patients with higher hepatic inflammation grades had more CCL5+ cells in their livers than those with lower grades (P < .05). However, the numbers of CCL5+ cells were not correlated with the fibrotic stages in CHB patients (r = .073, P = .61). The number of CCL5+ cells in the liver tissues of CHB patients was positively correlated with alanine transaminase levels (r = .278, P = .041) and aspartate aminotransferase levels (r = .328, P = .009). Conclusions: CHB patients have a significant accumulation of CCL5+ cells in the liver, and CCL5 may play a pathological role in hepatic inflammation of CHB.

🔖

Bu Makaleye Atıf Yap

ZHAO, X., WANG, J., CHANG, H., LİU, Y., CHEN, Y., CHEN, G., HUANG, R., WU, C. (2021). Intrahepatic Expression of C-C Motif ligand 5 in Patients with Chronic Hepatitis B. Turkish Journal of Gastroenterology, Cilt: 32 - Sayı: 1, 76–81. https://ajindex.com/articles/408859

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Zampino R, Boemio A, Sagnelli C, et al. Hepatitis B virus burden in developing countries. World J Gastroenterol. 2015
  2. 21(42):11941- 11953. [CrossRef] 2. Kwon SY, Lee CH. Epidemiology and prevention of hepatitis B virus infection. Korean J Hepatol. 2011
  3. 17(2):87-95. [CrossRef] 3. Bertoletti A, Le Bert N. Immunotherapy for chronic hepatitis B virus infection. Gut Liver. 2018
  4. 12(5):497-507. [CrossRef] 4. Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology. 2015
  5. [CrossRef] 5. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012
  6. 380(9859):2095-2128. [CrossRef] 6. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol. 2005
  7. 34(6):1329-1339. [CrossRef] 7. Chen XJ, Ye HH, Xing LX, et al. Association of mRNA expression level of IP-10 in peripheral blood mononuclear cells with HBV-associated acute-on-chronic liver failure and its prognosis. Hua Zhong Keji Da Xue Xuebao Yixue Yingdewen Ban. 2017
  8. Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol. 2014
  9. 14(3):181-194. [CrossRef] 9. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012
  10. 18(7):1028-1040. [CrossRef] 10. Wu HL, Kao JH, Chen TC, et al. Serum cytokine/chemokine profiles in acute exacerbation of chronic hepatitis B: clinical and mechanistic implications. J Gastroenterol Hepatol. 2014
  11. 29(8):1629- 1636. [CrossRef] 11. Zaldivar MM, Pauels K, von Hundelshausen P, et al. CXC chemokine ligand 4 (CXCL4) is a platelet-derived mediator of experimental liver fibrosis. Hepatology. 2010
  12. 51(4):1345-1353. [CrossRef] 12. Baeck C, Wei X, Bartneck M, et al. Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice. Hepatology. 2014
  13. 59(3):1060-1072. [CrossRef]